Related Experiment Video

Updated: Jun 5, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial

Walter Desmet1, Jan Bogaert, Christophe Dubois

  • 1Department of Cardiovascular Medicine, University Hospitals Leuven, Gasthuisberg, Herestraat 49, Leuven, Belgium. walter.desmet@uzleuven.be

European Heart Journal
|January 4, 2011
PubMed

Insights

Selective intracoronary adenosine did not improve myocardial salvage or reduce microvascular obstruction in ST-elevation myocardial infarction (STEMI) patients. This study found no benefit from this specific adenosine administration in STEMI treatment.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiovascular Research

Background:

  • Intravenous adenosine shows promise in improving myocardial reperfusion and reducing infarct size in ST-elevation myocardial infarction (STEMI).
  • Previous studies on intracoronary adenosine in STEMI have yielded conflicting results regarding its efficacy.
  • Microvascular obstruction (MVO) and myocardial salvage are critical determinants of outcomes following STEMI.

Purpose of the Study:

  • To evaluate the effectiveness of selective intracoronary adenosine administration in enhancing myocardial salvage and decreasing microvascular obstruction in STEMI patients.
  • To assess whether adenosine delivered distal to the occlusion site before balloon inflation improves cardiac outcomes.
  • To compare myocardial salvage index (MSI) and MVO using cardiac magnetic resonance imaging (MRI) between adenosine and placebo groups.

Main Methods:

  • A prospective, single-centre, double-blind, placebo-controlled clinical study involving 112 STEMI patients.
  • Patients received either selective intracoronary adenosine (4 mg) or placebo distal to the occlusion site before primary percutaneous coronary intervention.
  • Cardiac MRI was used to assess myocardial salvage index (MSI) and microvascular obstruction (MVO) on Days 2-3 post-intervention.

Main Results:

  • No significant difference in MSI was observed between the adenosine and placebo groups (41.3% vs. 47.8%, P = 0.52).
  • The extent of MVO was comparable, with a non-significant trend favoring placebo (2.4 g vs. 5.9 g, P = 0.07).
  • Key indicators of reperfusion, including TIMI flow grade and myocardial blush grade, were similar between groups.

Conclusions:

  • Selective high-dose intracoronary adenosine administration did not result in increased myocardial salvage in STEMI patients.
  • This treatment strategy did not lead to a significant decrease in microvascular obstruction.
  • The findings do not support the use of selective intracoronary adenosine for myocardial salvage in STEMI.
Abstract

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...